{
  "abstract": "Introduction: Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.\n\nCase Summary: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.\n\nConclusions: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India",
    "Department of Cardiology, Kashmir Medical College and Hospital, I.E Sempora Medicity, Srinagar, Jammu and Kashmir, India"
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Nimisha Musthafa Hafeesa"
    },
    {
      "affs": [
        1
      ],
      "name": "Gulbadin Mufti"
    },
    {
      "affs": [
        0
      ],
      "name": "Harikrishnan Sivadasanpillai"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a5qqr80cmcykw.bib",
  "cited_by": 1,
  "doi": "10.1016/j.jaccas.2026.109931",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13698926/",
  "id": "a5qqr80cmcykw",
  "issns": [
    "2666-0849"
  ],
  "landing_url": "https://doi.org/10.1016/j.jaccas.2026.109931",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Cardio-Oncology"
    ],
    [
      "heading",
      "Clinical Case Series"
    ],
    [
      "lcc",
      "RC666-701"
    ],
    [
      "openalex",
      "2740|Pulmonary Hypertension Research and Treatments"
    ]
  ],
  "openalex": "W7203834549",
  "pdf_url": "https://www.jacc.org/doi/pdf/10.1016/j.jaccas.2026.109931?download=true",
  "pmcid": "PMC13698926",
  "pmid": "42622591",
  "published": "2026-08-20",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/a5qqr80cmcykw.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:37Z",
      "native_id": "PMC13698926",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.jaccas.2026.109931"
    },
    {
      "first_seen": "2026-10-30T13:43:16Z",
      "native_id": "ea547ba73d79416ebce97f4f68dafc82",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.jaccas.2026.109931"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC666-701",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Dasatinib-Induced Pulmonary Arterial Hypertension",
  "title_text": "Dasatinib-Induced Pulmonary Arterial Hypertension",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:16Z",
  "url": "https://research.draconitic.com/paper/a5qqr80cmcykw",
  "venue": "JACC Case Reports",
  "versions": []
}